Johnson & Johnson lifts guidance on strong Q2 sales, shares pop.
US healthcare company Johnson & Johnson raised on Wednesday lifted annual earnings and sales guidance on the back of strong sales and foreign exchange tailwinds, sending shares in the firm up 5.5%.
Johnson & Johnson
16 July 2025 15:35:50
Source: Sharecast
The drug and medical equipment maker posted a rise in second-quarter sales to $23.7bn year-on-year, beating the $22.8bn forecast by analysts. Earnings per share came in at $2.77 compared with estimates of $2.68.
Adjusted sales growth for the full year was now expected to be 3.2 – 3.7%, up from 2-3%. J&J now expects full-year sales, including the impact of foreign currency, in the range of $93.2bn - $93.6bn, up from an April forecast of $91bn - $91.8bn when the company said it was $400m in costs related to tariffs.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.